Hexarelin (also known as Examorelin) is a synthetic six-amino acid growth hormone secretagogue (GHS) belonging to the GHRP (Growth Hormone-Releasing Peptide) family. It acts primarily by binding to the ghrelin receptor (GHS-R1a), stimulating robust growth hormone release from the anterior pituitary gland. Unlike endogenous ghrelin, Hexarelin does not significantly stimulate appetite-related pathways, making it of particular interest in targeted GH-axis research.
In preclinical research settings, Hexarelin has been investigated for its effects on the somatotropic axis, including IGF-1 modulation, and has demonstrated notable cardioprotective properties independent of its GH-releasing activity. Studies have explored its potential role in cardiac function, ventricular remodelling, and protection against ischaemic injury, attributed in part to binding at cardiac CD36 receptors.
Additional research has examined Hexarelin’s influence on body composition, bone density, and neuroprotection in animal models. Its high receptor binding affinity and potency make it a valuable tool compound in endocrinology and metabolic research.
Molecular Formula
C₄₇H₅₈N₁₂O₆
Molecular Weight
887.05 g/mol
Purity
>98%
CAS Number
140703-51-1
Form
Lyophilised Powder
Research Applications
Growth hormone secretion research, Cardiac function and cardioprotection studies, IGF-1 axis modulation, Body composition research, Neuroprotection studies, Endocrinology and metabolic research
For research purposes only. Not for human use.
Reviews
There are no reviews yet.